Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda

Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs.The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.Merck said last week its biggest tariff exposure is through Keytruda and it has enough US inventory for this year. It estimated$200 million in additional costs for the levies implemented to ...